We are live on ! Find out more
EDIT icon

Editas Medicine

229 hedge funds and large institutions have $188M invested in Editas Medicine in 2024 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 68 increasing their positions, 64 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more call options, than puts

Call options by funds: $1.5M | Put options by funds: $1.14M

6% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 64

1.71% less ownership

Funds ownership: 68.57%66.86% (-1.7%)

3% less funds holding

Funds holding: 235229 (-6)

12% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 41

29% less capital invested

Capital invested by funds: $263M → $188M (-$75.6M)

Holders
229
Holders Change
-6
Holders Change %
-2.55%
% of All Funds
3.29%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
36
Increased
68
Reduced
64
Closed
41
Calls
$1.5M
Puts
$1.14M
Net Calls
+$362K
Net Calls Change
-$415K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$27.4M +$1.05M +242,192 +3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$22.8M -$5.89M -1,352,998 -17%
DTC
3
Deep Track Capital
Connecticut
$16.7M -$4.79M -1,099,666 -18%
Millennium Management
4
Millennium Management
New York
$11.4M +$3.88M +891,227 +36%
State Street
5
State Street
Massachusetts
$8.4M -$9.27M -2,128,891 -46%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$7.73M -$339K -77,944 -3%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$6.44M -$340K -78,126 -4%
APM
8
Avidity Partners Management
Texas
$5M +$2.83M +649,000 +80%
Two Sigma Investments
9
Two Sigma Investments
New York
$4.63M +$3.56M +818,001 +151%
Morgan Stanley
10
Morgan Stanley
New York
$4.46M +$1.69M +388,961 +42%
Pictet Asset Management
11
Pictet Asset Management
Switzerland
$4.02M -$1.18M -271,340 -19%
Goldman Sachs
12
Goldman Sachs
New York
$3.98M -$224K -51,493 -4%
Two Sigma Advisers
13
Two Sigma Advisers
New York
$3.85M +$1.19M +272,500 +32%
WP
14
Woodline Partners
California
$3.07M -$305K -70,070 -7%
UBS AM
15
UBS AM
Illinois
$3.06M -$17.8K -4,090 -0.5%
Bank of America
16
Bank of America
North Carolina
$3.01M +$1.49M +342,513 +63%
Jane Street
17
Jane Street
New York
$2.95M +$2.5M +573,628 +198%
JP Morgan Chase
18
JP Morgan Chase
New York
$2.63M -$122K -28,018 -4%
Northern Trust
19
Northern Trust
Illinois
$2.4M -$146K -33,546 -5%
Stifel Financial
20
Stifel Financial
Missouri
$2.13M +$747K +171,656 +38%
Charles Schwab
21
Charles Schwab
California
$2.1M -$505K -116,105 -16%
RJA
22
Raymond James & Associates
Florida
$1.91M +$150K +34,556 +7%
KCM
23
Kennedy Capital Management
Missouri
$1.84M +$1.77M +407,487 +307%
Jacobs Levy Equity Management
24
Jacobs Levy Equity Management
New Jersey
$1.81M +$1.32M +302,652 +133%
Wells Fargo
25
Wells Fargo
California
$1.72M +$1.4M +321,888 +176%

EDIT Hedge Fund Activity: Q3 2024 in Review

229 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q3 2024, worth a combined $188M — down 29% from $263M a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of EDIT and 36 opened new positions — a net loss of 5 holders — while 64 trimmed existing stakes and 68 added.

The largest buyer was Millennium Management, adding an estimated $3.88M. The largest seller was State Street, cutting an estimated $9.27M.

  • 229 institutional investors held Editas Medicine (EDIT) as of Q3 2024, down from 235 in Q2 2024.
  • Funds reported $188M of Editas Medicine stock for Q3 2024, down 29% quarter-over-quarter.
  • 36 funds opened new Editas Medicine positions in Q3 2024 and 41 closed out, a net change of -5 holders.
  • The largest Editas Medicine buyer in Q3 2024 was Millennium Management, an estimated $3.88M added.
  • The largest Editas Medicine seller in Q3 2024 was State Street, an estimated $9.27M sold.

Based on aggregated 13F filings for Q3 2024.